Evidence map›Paper›PMID 37673924›Full record

ArticleNature communications2023

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine.

Eva Stadler, Mohamed Maiga, Lukas Friedrich, Vandana Thathy, Claudia Demarta-Gatsi, Antoine Dara, Fanta Sogore, Josefine Striepen, Claude Oeuvray, Abdoulaye A Djimdé and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Eva Stadler *The Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.ORCID http://orcid.org/0000-0002-5129-8180
Mohamed Maiga *Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali.ORCID http://orcid.org/0000-0003-1537-9087
Lukas Friedrich *Medicinal Chemistry & Drug Design Global Research & Development, Discovery Technologies, Merck Healthcare, 64293, Darmstadt, Germany.
Vandana Thathy *Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Claudia Demarta-GatsiGlobal Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland.ORCID http://orcid.org/0000-0002-9610-2962
Antoine DaraUniversité des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali.ORCID http://orcid.org/0000-0002-7739-4437
Fanta SogoreUniversité des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali.
Josefine StriepenDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0003-4673-3114
Claude OeuvrayGlobal Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland.
Abdoulaye A DjimdéUniversité des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali.ORCID http://orcid.org/0000-0003-0062-2283
Marcus C S LeeWellcome Sanger Institute, Wellcome Genome Campus, CB10 1SA, Hinxton, UK.ORCID http://orcid.org/0000-0002-4973-0915
Laurent DembéléUniversité des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, PB1805, Bamako, Mali. laurent@icermali.org.
David A FidockDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, 10032, USA. df2260@cumc.columbia.edu.ORCID http://orcid.org/0000-0001-6753-8938
David S KhouryThe Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia. dkhoury@kirby.unsw.edu.au.ORCID http://orcid.org/0000-0002-2663-1551
Thomas SpangenbergGlobal Health Institute of Merck, Ares Trading S.A., (an affiliate of Merck KGaA, Darmstadt, Germany), 1262, Eysins, Switzerland. thomas.spangenberg@merckgroup.com.ORCID http://orcid.org/0000-0002-5654-8919

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37673924
PMCPMC10482846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.